International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (1193-1200), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Diagnosis and Treatment Approaches of Irritable Bowel Syndrome (IBS) Recurrent Abdominal Pain (RAP) & in Children: An Overview

[1]Trke Mohammed A. Alhazmi, [2]Abdulaziz Ramdan H. Almatrafi, [3]Maali Jalal Alali, [4]Khalid Mohammed D. Alshammari, [5]Wejdan Ahmed Albarqi, [6]Hussain Ali S Alhazmi, [7]Alanoud Musead Alhalwan, [8]Alanazi, Nasser Salem M

Abstract: **This review was aiming to overview the irritable bowel syndrome (IBS) Recurrent abdominal pain (RAP) in children from different perspectives, and to discuss in details the diagnosis procedures that could be used for detecting IBS, then to review the treatment approaches for these combined complicated conditions. This review was aiming to overview the irritable bowel syndrome (IBS) Recurrent abdominal pain (RAP) in children from different perspectives, and to discuss in details the diagnosis procedures that could be used for detecting IBS, then to review the treatment approaches for these combined complicated conditions.IBS is not considered a medical diagnosis of exemption that can just be made after performing a battery of costly diagnostic tests. Rather, IBS needs to be confidently identified in the center at the time of the very first check out using the Rome III requirements and a mindful history and physical examination. Treatment choices for IBS have actually increased in number in the past years and clinicians should not be restricted to utilizing only fiber supplements and smooth muscle relaxants. Abdominal pain, bloating, irregularity and diarrhea are the 4 main signs that can be resolved using a mix of dietary interventions and medications. Treatment options consist of probiotics, antibiotics, tricyclic antidepressants, selective serotonin reuptake inhibitors and representatives that modulate chloride channels and serotonin.**

Keywords: **Irritable Bowel Syndrome (IBS), Recurrent abdominal pain (RAP), Treatment.**

1. INTRODUCTION

Irritable bowel syndrome (IBS) is among the most common reasons for reoccurring abdomina pain in the pediatric population [(1)]. Studies have approximated the frequency of IBS to range in between 6% and 14% in children and between 22.0% and 35.5% in adolescents [(2,3)]. Moreover, IBS has a considerable impact on quality of life of afflicted children, which highlights the scientific value of the disease [(4)].

Reoccurring abdominal pain (RAP) of youth is an important function of IBS. RAP was first described by Apley and Naish following their pioneering study of 1000 children in Bristol, United Kingdom [(5)]. Apley defined RAP as three or more episodes of abdominal pain occurring over a duration of a minimum of 3 months, with pain enough to trigger some impairment of function [(5)]. This definition of RAP still is and stands in current use globally.

Frequent abdominal pain and irritable bowel syndrome are 2 examples of practical gastrointestinal disorders (FGID) which are conditions that include a mix of signs that are persistent or persistent and cannot be explained entirely with current structural or biochemical investigations. The term 'functional' highlights that a lot of these symptoms might accompany regular advancement (e.g., infant regurgitation) or may be a reaction to otherwise normal internal or external cues (e.g., irregularity after agonizing stooling) [(6)]. As there is a strong familial pattern noted in IBS, there has actually been a continuous interest in discovering a genetic link in IBS. Far, a favorable association in between IBS and interleukin-10 (IL-

10) polymorphism has been reported. A research study in Taiwan with 94 children with IBS and 102 healthy controls, significantly lower Escherichia coli lipopolysaccharide-induced IL-10 production by peripheral blood mononuclear cells was kept in mind in children with IBS although the study group concluded that this reduction in IL-10 production may not have actually been totally figured out genetically [7]. Patients with a mutation in a sodium channel gene (SCN5A) were found to report intestinal signs particularly stomach pain more often, and this mutation might be a contributory consider IBS [8,9].

IBS as described by the Rome III criteria (**Table1**) [10] consists of weekly symptoms of stomach pain or discomfort accompanied by modifications in bowel patterns. These include changes in defecation type or frequency at the beginning of pain and/or relief of pain with defecation [10]. Trimebutine maleate, an opioid agonist that acts on the peripheral delta, mu and kappa receptors, is utilized in the treatment of IBS [11].

Table 1: Rome III diagnostic criteria for childhood irritable bowel syndrome [10]

A. Abdominal discomfort or pain associated with 2 or more of the following (present at least 25% of the time):
B. Improved after defecation
C. Onset of symptoms associated with a change in stool frequency
D. Onset associated with a change in stool form alternating between diarrhea and constipation
E. No evidence of an inflammatory, anatomic, metabolic, or neoplastic process that explains the child's symptoms
F. The above criteria should be fulfilled at least once per week for at least 2 mo before a diagnosis of irritable bowel syndrome is made.

The above criteria should be fulfilled at least once per week for at least 2 months before a diagnosis of irritable bowel syndrome is made.

Objectives:

This review was aiming to overview the irritable bowel syndrome (IBS) Recurrent abdominal pain (RAP) in children from different perspectives, and to discuss in details the diagnosis procedures that could be used for detecting IBS, then to review the treatment approaches for these combined complicated conditions.

2. METHODS

Detailed computerized search of literature was performed through several medical databases; Midline/PubMed, Science direct, and Embase, search was conducted to find relevant studies discussing the irritable bowel syndrome (IBS) Recurrent abdominal pain (RAP) in children, and especially those which was concerned with the diagnosis and treatment approaches, and were published up to December 2016 in English language, and only containing human subjects. Furthermore, references of each identified studies were searched for more identical studies to our study purpose.

3. RESULTS

- ***Pathophysiology of IBS&RAP (FGID):***

Several factors are thought to add to FGIDs. Although early evidence recommended motility disturbances as a significant perpetrator, present proof suggests that patients with functional bowel disease may have unusual intestinal reactivity to physiologic stimuli (dietary, gut distension, hormone), toxic stimuli (inflammation), and/or psychological stress. This is termed visceral hypersensitivity and is believed to originate from a dysregulation in the interaction in between the enteric nervous system and the main nerve system [12]. The concern that is to be answered is whether the absence of coordination is primarily enteric or central in origin.

A current study by Naliboff et al. [13] showed that adult patients with IBS have hypersensitivity to rectal distension that gradually normalizes with time, recommending a process of habituation to visceral sensation. These patients' reports of IBS signs did not alter over that same time duration. Utilizing practical brain imaging (positron emission tomography- PET screening) they discovered that visceral input was consistent during the time of the research study, but the functional connection within the central networks (specifically those locations of the brain related to caution and arousal) was

minimized [13]. This recommends that despite consistent input from the visceral afferents, processing and understanding of this input can be modified through habituation of main brain areas; the presence of the balloon is noted however the brain does not respond as it did previously. However, children with FGID do have visceral hypersensitivity. Faure and colleagues studied children with FAP and IBS compared with Control children and those with functional dyspepsia [14]. Utilizing rectal balloon distention with a barostat (a device that maintains continuous compliance as it distends) they showed that children with FAP and IBS picked up rectal pain at a lower pressure limit (mean 16 mm Hg and 19.5 mm Hg, respectively) compared to Controls and children with dyspepsia (42 mm Hg and 41.5 mm Hg, respectively). Further, the pain described the T8 to L1 dermatomes (i.e., abdominal projections) in the FAP and IBS children whereas it described the S3 dermatome (perineal) in the Control and dyspepsia groups [14]. These findings of visceral hypersensitivity fit with the observations of Crandall et al. who determined pain symptoms after colonoscopy in 20 children with FGID (19 IBS, 1 FAP) compared with 20 children with inflammatory bowel disease (15 Crohn, 5 ulcerative colitis). Children with FGID had greater baseline pain scores and a longer period of pain post-procedure than did children with inflammatory bowel disease [15].

Another important factor associated with the pathophysiology of FGIDs is the psychosocial part. It has been clear for some time that there is a relationship between the psychological state of the parent and child and the experience of RAP [16]. Walker et al. [17] have actually extended these findings to show that compared to Control children, children with RAP were less positive about their capability to deal with day-to-day tension. Further, they were less likely to use accommodative coping techniques such as accepting the stress factor, reframing its significance, or motivating themselves to keep going [17]. These observations fit with those of Kaminsky and associates who revealed that depressive symptoms in children with RAP straight related to passive coping and inversely related to self-efficacy and social assistance [18]. How a child deals with stress factors might be one of the crucial factors in persistent abdominal pain and depressive signs. They surmised that children who are able to deal with pain appropriately are less likely to experience depressive sensations of vulnerability [18].

- ***Genetics background of IBS:***

Current evidence for an IBS gene is admittedly restricted at present. Notably, numerous research studies suggest that IBS and other gastrointestinal symptoms do run in families-- an important feature of genetic diseases. When asked if they have a family member with IBS, approximately 33% of outpatients with IBS will report a favorable family history of IBS, compared to 2% of outpatient controls [19]. Furthermore, when specific relationships have been examined, 26 - 34% of patients will have a parent with IBS, compared to 13% of control patients [20]. Furthermore, children of moms and dads with IBS are likewise twice as likely to see a provider for abdominal problems as children of moms and dads without IBS [21]. Young person who as children had persistent abdominal pain were nearly three times as likely to have consistent IBS-like symptoms at 5 -13 year of follow-up if there was a concurrent brother or sister with abdominal pain [22]. A significant constraint of the bulk of these studies is that the IBS status of the loved ones were collected from the patient, but not collected or validated in the relative. In another research study where relative were directly queried regarding bowel signs, between 54 and 68% of patients with IBS had actually an impacted first-degree relative, compared to 19 - 36% of controls without IBS [23]. Overall, it was approximated that in between 15 and 37% of case-relatives are impacted with IBS, compared to 4 -16% of control-relatives, depending upon whether the source of the info was the proband, the getting involved family members, or a mix of both sources, whereby the proband data about family members were utilized when data from a particular relative were not readily available.

Twin research studies represent a particular kind of family study that offers a distinct opportunity to recognize the hereditary and environmental factors to disease. Because monozygotic twins share the exact very same hereditary code and dizygotic twins share half of the very same genetic code, comparing concordance rates between dizygotic and monozygotic twins allows the chance to quantitate the contributions that genetics and environment each make to the development of the disease. Five twin studies demonstrate that the hereditary contribution to IBS appears to variety in between 0 and 20% [24,25,26,27,28].

Standard genetic diseases were unusual diseases triggered by a couple of or single major mutations in a single gene that were sent through families in a predictable (i.e., autosomal dominant or autosomal recessive) manner [27,28]. On the other hand, IBS is not an unusual, lethal disease, and thus, is unlikely to be a classic Mendelian disease that is caused by one gene. Rather, if there is certainly a hereditary basis for IBS, IBS is likely a "complicated genetic disease," caused by numerous genes that communicate with environmental risk factors to lead to IBS symptoms. Moreover, the hereditary variants responsible for IBS may be typically present in the general population, and each hereditary version might have a "weak" result, leading to IBS signs that may not be easy to find. As illustrated in (**Figure 1**) [28], the irregularity in the clinical presentation of IBS may, in part, be explained by a hidden hereditary and environmental heterogeneity. This paradigm, at present, is speculative, and additional studies are needed to successfully recognize the genes for IBS, if they certainly exist [28].



Figure1: IBS may be a complex genetic disease caused by multiple genes (represented by genes A–F) with one or multiple genetic variations (arrows) of modest effect responsible for IBS symptoms. The clinical heterogeneity of IBS may perhaps be explained by the underlying genetic heterogeneity. [28]

- ***Diagnosis approaches of IBS:***

In the absence of a conclusive lab or radiological diagnostic test, IBS remains a scientific diagnosis. We suggest following examinations to dismiss other serious gastrointestinal disorders: serological screening for celiac disease, inflammatory markers (ESR, C-reactive protein, plasma viscosity or orosomucoid) likely to be raised in inflammatory bowel disease (IBD), liver function tests (low serum albumin in IBD) and full blood count (unusual anemia, blood loss in IBD). In establishing countries, it is particularly essential to send out a stool sample for microscopy and culture with specific request to try to find ova, cyst and parasites [29].

The medical diagnosis of IBS is made after exclusion of natural causes of stomach pain and bowel modifications based upon history and examination particularly making sure that no red flag symptoms exist (**Table 2**) [29]. These organic causes consist of lactose intolerance, celiac disease and IBD. Signs concordant with the Rome III requirements need to assist clinicians to make a favorable diagnosis of IBS and prevent unnecessary examinations [10].

Table 2: Red flag symptoms [29]

A.	Night time pain or diarrhea
B.	Recurrent unexplained fever
C.	Recurrent or worsening rectal bleeding
D.	Joint pains
E.	History of weight loss and poor growth
F.	Family history of inflammatory bowel disease
G.	Persistence of severe vomiting or diarrhea
H.	Unexplained pallor
I.	Stools that may be difficult to flush away
J.	Delay in onset or progression of puberty

The medical diagnosis of a FGID such as FAP or IBS by definition precludes the ability to do an easy diagnostic test. Thus, the diagnosis must trust the history and physical examination with a degree of supporting tests. The definition of FAP, as laid out by the Pediatric Rome criteria, is continuous or episodic stomach pain that does not meet the criteria for any other FGID (e.g., gastroesophageal reflux, irregularity). Additionally, IBS is defined as abdominal pain or discomfort connected with a change in frequency or type of stool or eliminated with defecation. Both FAP and IBS need symptoms to be present at least when weekly for a minimum of 2 months before diagnosis and without proof of inflammatory, structural, metabolic, or neoplastic procedure to explain the signs [10].

A recent review performed by the American Academy of Pediatrics (AAP) and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) resulted in a suggestion that in absence of "alarm signs or indications" in the history and health examination, the medical care physician can detect and address a practical condition. Alarm functions consist of presence of blood in the stool, involuntary weight-loss, deceleration of direct development, significant vomiting (drawn-out or bilious), persistent severe diarrhea, consistent pain far from the umbilicus, unexplained fever, family history of inflammatory bowel disease, or unusual physical examination finding (e.g., organomegaly, inflammation away from the umbilicus, costovertebral angle inflammation, perianal abnormalities). In the existence of these findings, it is generally indicated to pursue more diagnostic screening [(12)]. The usefulness of these alarm signs seems self-evident, their validity has not been evaluated. Undoubtedly, our study revealed that the location of the stomach pain does not distinguish between children with RAP and typical children without RAP who occasionally have stomach pain [(30)].

Fishbein et al. [(31)] surveyed charts and found that a lot of medical care physician's minimal diagnostic tests in patients who provide with normal findings of FAP. They did note, however, that physicians were more likely to order a stomach ultrasound despite their belief that it would not change the diagnosis. The assumed rationale was that primary care physicians were using unfavorable outcomes of a non-invasive ultrasound as a transition from a diagnostic conversation to reviewing treatment options for patients [(31)]. Although a plain radiograph of the abdomen commonly is carried out in the assessment of FGID, Bongers et al. examined the readily available literature and concluded that it does not have a role in the evaluation of FAP [(32)]. Even for the diagnosis of irregularity, the inter- and intraindividual variation among radiologists is undue for a radiograph to provide helpful information.

- ***Treatment of IBS&RAP:***

Smooth muscle relaxants Therapy for stomach pain over the past 20 years has concentrated on using smooth muscle relaxants (typically called antispasmodics). Although there are ample theoretical grounds for recommending these medications, medical experience has been disappointing. Most studies that have looked at these medications have actually been poorly created, inadequately managed, and have not shown considerable advantages above placebo (33). Nevertheless, some patients improve with antispasmodic drugs, particularly those whose signs are caused by meals and those who suffer tenesmus. When utilized for meal-induced signs, anticholinergics must be recommended 30-- 60 minutes prior to meals so that peak serum levels of the drug accompany peak signs.

A current meta-analysis of 22 studies involving 1778 patients and 12 various antispasmodic agents showed modest enhancements in global IBS symptoms and abdominal pain [(34)]. All IBS subtypes were consisted of in the analysis. Regrettably, few of the agents examined are offered in the US. An US study discovered that dicyclomine hydro-chloride improved stomach pain, tenderness, international functioning, and bowel habits in patients with IBS. Nevertheless, up to 68% of patients suffered side effects when offered the high dosage required to enhance stomach pain [(35)].

Tricyclic antidepressants Tricyclic antidepressants (TCAs) have been utilized to deal with functional bowel conditions for over 3 years. Several TCAs (amitriptyline, nortriptyline, desipramine) have actually been studied in patients with IBS, although adverse effects (i.e. worsening constipation in patients with IBS and irregularity) can restrict their restorative capacity. Just 7 studies have actually been performed to date, and many of these were of restricted duration and consisted of only a little number of patients [(36,37)].

Probiotics are live microbes that when administered in adequate amounts provide a helpful health effect on the host. Research studies in adults have actually suggested a benefit for some strains of probiotics in dealing with individuals with IBS [(38)]. Gawronska et al. carried out a randomized double-blind placebo-controlled research study utilizing Lactobacillus GG in children with dyspepsia, FAP, or IBS. The outcomes suggested a moderate benefit in increasing the variety of children with no pain however there was no decrease in pain frequency or intensity and the confidence periods were big [(39)]. These results normally fit with those of Bausserman and Michail who found no advantage with Lactobacilllus GG in children with IBS [(40)]. Further studies with different pressures of probiotics will be needed to concern definite conclusions.

Cognitive-behavioral treatment has actually worked in improving pain and disability result over the short term. When the education consists of the child and the parent and focuses on self-coping and care-giving techniques [(12,41,42)], this treatment is most efficient. Recent work by Weydert et al. has broadened these findings. After getting baseline pain journals and psychological testing (depression, stress and anxiety, somatization scales in children and parents), children with RAP were randomized to get either breathing workouts alone or guided imagery therapy with progressive muscle relaxation. Guided imagery is a form of self-regulation therapy where deep relaxation is caused using progressive muscle relaxation permitting the subject to be assisted in developing images that help with resolution of determined problems [(43)].

4. CONCLUSION

IBS is not considered a medical diagnosis of exemption that can just be made after performing a battery of costly diagnostic tests. Rather, IBS needs to be confidently identified in the center at the time of the very first check out using the Rome III requirements and a mindful history and physical examination. Treatment choices for IBS have actually increased in number in the past years and clinicians should not be restricted to utilizing only fiber supplements and smooth muscle relaxants.

Abdominal pain, bloating, irregularity and diarrhea are the 4 main signs that can be resolved using a mix of dietary interventions and medications. Treatment options consist of probiotics, antibiotics, tricyclic antidepressants, selective serotonin reuptake inhibitors and representatives that modulate chloride channels and serotonin.

REFERENCES

[1] Chiou E, Nurko S. Functional abdominal pain and irritable bowel syndrome in children and adolescents. Therapy. 2011;8:315–331.

[2] Hyams JS, Burke G, Davis PM, Rzepski B, Andrulonis PA. Abdominal pain and irritable bowel syndrome in adolescents: a community-based study. J Pediatr. 1996;129:220–226.

[3] Miele E, Simeone D, Marino A, et al. Functional gastrointestinal disorders in children: an Italian prospective survey. Pediatrics. 2004;114:73–78.

[4] Varni JW, Lane MM, Burwinkle TM, et al. Health-related quality of life in pediatric patients with irritable bowel syndrome: a comparative analysis. J Dev Behav Pediatr. 2006;27:451–458.

[5] Apley J, Naish N. Recurrent abdominal pains: a field survey of 1,000 school children. Arch Dis Child. 1958;33:165–170.

[6] Hyman PE, Milla PJ, Benninga MA, Davidson GP, Fleisher DF, Taminiau J. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology. 2006;130:1519–1526.

[7] Hua MC, Chao HC, Yao TC, Lai MW, Huang JL; PATCH Study Group. Investigation of interleukin-10 promoter polymorphisms and interleukin-10 levels in children with irritable bowel syndrome. Gut Liver. 2013;7:430–436.

[8] Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut. 2003;52:91–93.

[9] Locke GR 3rd, Ackerman MJ, Zinsmeister AR, Thapa P, Farrugia G. Gastrointestinal symptoms in families of patients with an SCN5A-encoded cardiac channelopathy: evidence of an intestinal channelopathy. Am J Gastroenterol. 2006;101:1299–1304.

[10] Rasquin A, Di Lorenzo C, Forbes D, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology. 2006;130:1527–1537.

[11] Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997;25:225–246.

[12] Di LC, Colletti RB, Lehmann HP, Boyle JT, Gerson WT, Hyams JS, Squires RH, Jr, Walker LS, Kanda PT. Chronic abdominal pain in children: a clinical report of the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2005;40:245–248.

[13] Naliboff BD, Berman S, Suyenobu B, Labus JS, Chang L, Stains J, Mandelkern MA, Mayer EA. Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. Gastroenterology. 2006;131:352–365.

[14] Faure C, Wieckowska A. Somatic referral of visceral sensations and rectal sensory threshold for pain in children with functional gastrointestinal disorders. J Pediatr. 2007;150:66–71.

[15] Crandall WV, Halterman TE, Mackner LM. Anxiety and pain symptoms in children with inflammatory bowel disease and functional gastrointestinal disorders undergoing colonoscopy. J Pediatr Gastroenterol Nutr. 2007;44:63–67.

[16] Walker LS. The evolution of research on recurrent abdominal pain: History, assumptions, and a conceptual model. In: McGrath PJ, Finley GA, editors. Chronic and Recurrent Pain in Children and Adolescents Progress in Pain Research and Management. 1999.

[17] Walker LS, Smith CA, Garber J, Claar RL. Appraisal and coping with daily stressors by pediatric patients with chronic abdominal pain. J Pediatr Psychol. 2007;32:206–216.

[18] Kaminsky L, Robertson M, Dewey D. Psychological correlates of depression in children with recurrent abdominal pain. J Pediatr Psychol. 2006;31:956–966.

[19] Whorwell PJ, McCallum M, Creed FH, et al. Non-colonic features of irritable bowel syndrome. Gut. 1986;27:37–40.

[20] Kanazawa M, Endo Y, Whitehead WE, et al. Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychological distress. Dig Dis Sci. 2004;49:1046–53.

[21] Levy RL, Whitehead WE, Von Korff MR, et al. Intergenerational transmission of gastrointestinal illness behavior. Am J Gastroenterol. 2000;95:451–6.

[22] Pace F, Zuin G, Di Giacomo S, et al. Family history of irritable bowel syndrome is the major determinant of persistent abdominal complaints in young adults with a history of pediatric recurrent abdominal pain. World J Gastroenterol. 2006;12:3874–7.

[23] Saito YA, Zimmerman JM, Harmsen WS, et al. Irritable bowel syndrome aggregates strongly in families: A family-based case-control study. Neurogastroenterol Motil. 2008;7:790–7.

[24] Levy RL, Jones KR, Whitehead WE, et al. Irritable bowel syndrome in twins: Heredity and social learning both contribute to etiology. Gastroenterology. 2001;121:799–804.

[25] Morris-Yates A, Talley NJ, Boyce PM, et al. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol. 1998;93:1311–7.

[26] Mohammed I, Cherkas LF, Riley SA, et al. Genetic influences in irritable bowel syndrome: a twin study. Am J Gastroenterol. 2005;100:1340–4.

[27] Bengtson MB, Ronning T, Vatn MH, et al. Irritable bowel syndrome in twins: Genes and environment. Gut. 2006;55:1754–9.

[28] Lembo A, Zaman M, Jones M, et al. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: A twin study. Aliment Pharmacol Ther. 2007;25:1343–50.

[29] Sandhu BK, Paul SP. Irritable bowel syndrome in children: Pathogenesis, diagnosis and evidence-based treatment. *World Journal of Gastroenterology : WJG*. 2014;20(20):6013-6023. doi:10.3748/wjg.v20.i20.6013.

[30] Shulman RJ, Eakin MN, Jarrett M, Czyzewski DI, Zeltzer LK. Characteristics of pain and stooling in children with recurrent abdominal pain. J Pediatr Gastroenterol Nutr. 2007;44:203–208.

[31] Fishbein M, Bernard B, Ehrlich C. The primary care physician's approach to functional abdominal pain in childhood. J Clin Gastroenterol. 2006;40:497–503. [PubMed]Most primary care physicians are following current guidelines for diagnosing functional GI disorders by limiting the number of tests they are doing when alarm signs are absent.

[32] Bongers ME, Voskuijl WP, van Rijn RR, Benninga MA. The value of the abdominal radiograph in children with functional gastrointestinal disorders. Eur J Radiol. 2006;59:8–13.

[33] Poynard T., Regimbeau C., Benhamou Y. (2001) Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 15:355–361

[34] Ford A.C., Talley N.J., Spiegel B.M., Foxx-Orenstein A.E., Schiller L., Quigley E.M. et al. (2008a) Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 337:a2313.

[35] Page J.G., Dirnberger G.M. (1981) Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 3:153–156

[36] Lesbros-Pantoflickova D., Michetti P., Fried M., Beglinger C., Blum A.L. (2004) Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 20:1253–1269

[37] Jackson J.L., O'Malley P.G., Tomkins G., Balden E., Santoro J., Kroenke K. (2000) Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 108:65–72.

[38] O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541–551.

[39] Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther. 2007;25:177–184.

[40] Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr. 2005;147:197–201.

[41] Sanders MR, Rebgetz M, Morrison M, Bor W, Gordon A, Dadds M, Shepherd R. Cognitive-behavioral treatment of recurrent nonspecific abdominal pain in children: an analysis of generalization, maintenance, and side effects. J Consult Clin Psychol. 1989;57:294–300.

[42] Sanders MR, Shepherd RW, Cleghorn G, Woolford H. The treatment of recurrent abdominal pain in children: a controlled comparison of cognitive-behavioral family intervention and standard pediatric care. J Consult Clin Psychol. 1994;62:306–314.

[43] Weydert JA, Shapiro DE, Acra SA, Monheim CJ, Chambers AS, Ball TM. Evaluation of guided imagery as treatment for recurrent abdominal pain in children: a randomized controlled trial. BMC Pediatr. 2006;6:29.